Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
      Description

      This is a Phase I/II multicenter single arm non-randomized open label study of the investigational drug, brentuximab vedotin, given in combination with routine chemotherapy (rituximab, cyclophosphamide, doxorubicin and prednisone) every 3 weeks for a total of 6 cycles.

      Conditions
      CD30 Positive Primary Mediastinal Large B-cell LymphomaCD30-Positive Diffuse Large B-Cell LymphomaCD30-Positive Gray Zone Lymphoma
      Talk to us
      ACTIVE_NOT_RECRUITING
      Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
      Description

      This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma

      Conditions
      Anaplastic Large Cell LymphomaPeripheral T Cell LymphomaExtranodal NK/T-cell LymphomaDiffuse Large B Cell LymphomaPrimary Mediastinal Large B-Cell Lymphoma (PMBCL)
      Talk to us